Repeat Use Procedure: What Are The Steps To Consider?

In this article, we look at the issue of Repeat Use Procedures. We explain what a Repeat Use Procedure is, the steps to take and the pitfalls to avoid in completing a RUP.

Acorn Regulatory Regulatory Strategy ConsultantsWhat Is A Repeat Use Procedure?

According to the CMDh the ‘Repeat Use Procedure’(RUP) is the use of the Mutual Recognition Procedure (MRP) after the completion of a first MRP or Decentralised Procedure (DCP) for the recognition of a marketing authorisation by other Member States (MS).

This means that a marketing authorisation holder may use the MRP several times for the same marketing authorisation, once the first MRP is complete, to include additional member states (MS) that were not involved in the initial MRP.

For the initial MRP the Reference Member State (RMS) leads the administrative procedure and also prepares the Assessment Report (AR) which summarises the dossier and critically evaluates the safety, efficacy and quality of the medicinal product. This AR is made available to all Concerned Member States (CMS) by the RMS and the CMS then base their evaluation of the dossier on the AR, for this reason the dossier submitted to all of the member states must be identical. The MS have 90 days to accept the AR from the RMS and issue a marketing authorisation or if a ‘potential serious risk to public health’ is identified by a CMS the application will be sent for further discussion to the Coordination Group for Mutual Recognition and Decentralised Procedures (CMD(h)).

You should note that if the issue is not resolved within 60 days, the application is then sent to the CHMP for arbitration.

Steps To Consider In a Repeat Use Procedure

Prior to beginning a repeat use procedure, the MAH should:

  1. Ensure that all ongoing procedures are finalised:
  • Changes in RMS post-MRP
  • Withdrawal of the application during an earlier procedure
  • Variations
  • Harmonisation of labelling and package leaflet
  • Renewals
  • Updating of the dossier
  • Repeat use of ‘old Dossiers’
  1. Approximately 90 days before the submission, send a written request for the Repeat Use Procedure to the RMS and agrees a date of submission.

    • The RMS then writes an addendum to the original AR commenting on the changes made subsequently.
    • 14 days before the procedure is scheduled to start the MAH submits the application to the ‘New’ CMS according to Article 28(2) of EC Directive 2001/83 and the RMS circulates the updated AR to the CMSs.
    • The repeat use procedure is between the RMS and new CMS only and no changes are permitted during the procedure.

Would you like to get insights in your inbox?

Subscribe to the Acorn Regulatory monthly newsletter.

What Should Be Included In the Dossier?

The dossier submitted must comprise of:

  • the original dossier updated by any variation or renewal which has been approved or amended after authorisation.
  • A proposal for the SPC, PIL and labelling which should be identical to the currently authorised version.

The new CMS will validate the application as per the CMDh procedure for the automatic validation of MR Procedures for new applications.

Frequent Validation Issues

Some Frequent issues found on validation are:

  • Old dossiers might not always meet the meet updated guidelines/legislation example, pharmacovigilance.
  • Incomplete variations, renewals.
  • Legal basis issues
  • Expired certificates example, CEP/GMP

Conclusion

Provided there are no issues during the validation of the submission the procedure is started (day 0). All CMSs must send their comments to the RMS, CMS and applicant by day 30 and the applicant must respond to any queries by day 40. An evaluation of the responses is issued by the RMS by day 48. Any remaining comments are circulated by the CMS to the RMS and applicant by day 55. During days 55-59 the applicant and the RMS will communicate and clarify if the procedure can be closed at day 60 or if there is a requirement for further responses.

Following a successful procedure, the new CMS must recognise the MA of the product with the same SMPC. Labelling and package leaflet (PIL) that were approved in the previous MRP or DCP. However, the PIL must be updated at the end of the procedure to include the product names and the new CMS in section 6.

We have included further relevant articles below the web form that we hope will be of interest to you.

We Can Help

If you would like our assistance with your Repeat Use Process, then please contact us by using the form below. Alternatively, you can call us on 00353 52 61 76 706 or email us: info@acornregulatory.com.  We have almost twenty years of experience working with pharmaceutical companies on all aspects of regulatory affairs and our experienced team can assist you with any issue that you might have.

Further Reading

CMC & Pharmaceutical Regulatory Affairs Services

Our pharmaceutical regulatory affairs team is staffed by experts who have considerable expertise in the sector.  Every team member has at least 15 years of  experience in the pharmaceutical sector assisting pharmaceutical companies with their regulatory issues.  Since 2002, our pharmaceutical regulatory affairs specialists have been working with clients all over the world.

Read more about our team here.

Can You Use A U.S. Dossier To Apply For A European Marketing Authorisation?

Is it possible to use a U.S. dossier when applying for an E.U. marketing authorisation?  This is a question that is asked time and again.  We first published this article in 2017.  Below, we have updated it and included links to other relevant articles that will assist companies dealing with this issue. Read the article here.

Marketing Authorisation Holders – An Overview

Acorn Regulatory’s consultants are experts in the sector.    Members of our team have written extensively on this website and in other industry publications about the issues associated with marketing authorisations holders and much more.  Below we have highlighted just four articles that our team members have written on the subject in recent times. Read the full article about Marketing Authorisation Holders here.

Need A WDA? Read Our Step By Step Guide

There has been significant growth in the number of companies seeking a Wholesale Distribution Authorisation (WDA) in recent years.  We have assisted many companies with every step of the process. Here, we outline a step by step guide for obtaining a WDA.  Read the full article here.

How To Prepare For A Pharmacovigilance Inspection

A pharmacovigilance inspection can be a daunting prospect for many companies.  Since 2002 we have worked with countless companies to guide them through their inspections. We look at the measures that your company can take to be prepared.  Read the full article here.

How To Complete A Type I Variation

Type I Variations to a Marketing Authorisation are surprisingly difficult.  The procedure that many people perceive to be a simple process can prove to be otherwise.  This article looks at how to complete a type 1 variation and we will consider:

  • common deficiencies
  • common validation issues
  • the challenges posed by the eAF
  • what to do when documentation is missing
  • how to handle GMP variations
  • what happens when a CEP is presented for an active substance instead of a GMP certificate

After reading this article you will be better placed to complete a Type I Variation to a Marketing Authorisation while avoiding the common pitfalls outlined below.  Read the full article here.

What Are The Initial Steps in Applying for a Marketing Authorisation?

We consistently receive questions regarding the steps required when applying for a marketing authorisation (MA).  In this article, we aim to provide a guide to assist companies applying for an MA

We have also provided a number of links throughout the article to relevant articles, authorities, organisations, and pieces of legislation to assist you.  Read the full article here.

KASA – What You Need To Know About Knowledge-Aided Assessment and Structured Application

What is KASA and how will it impact on getting a drug assessed by the US FDA?  We look at its ‘3 pillars’ and what it aims to be.  Importantly, we look at how the FDA believes it will change how drugs are assessed in the United States of America.

Read more about KASA here.

About the Author:
Christine McGrath
Senior Regulatory Affairs Advisor
Christine McGrath is an experienced Senior Regulatory Affairs Advisor at Acorn Regulatory. She works with companies around the world on issues relating to pharmaceutical regulatory affairs. At present, she is also working with our Clinical team on a groundbreaking veterinary clinical trial. You can read more articles by Christine by clicking the link below.
Other articles by Christine